Compare Halliburton Company (HAL) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs Moderna, Inc. — how do they compare? Halliburton Company trades at $32.87 (market cap $29.33B), while Moderna, Inc. trades at $60.2 (market cap $23.60B). The key difference: Halliburton Company is the larger of the two by market cap, and Halliburton Company pays a 1.94% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| HAL | MRNA | |
|---|---|---|
Market Cap | $29.33B | $23.60B |
Sector | Energy | Health |
52-Week High | $42.98 | $81.80 |
52-Week Low | $20.50 | $22.36 |
Enterprise Value | $35.41B | $19.70B |
Dividend Yield | 1.94% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $35.56, up 0.97% on the day, with a bullish technical signal supported by moving averages. The company shows solid fundamentals with a P/E of 19.46 and ROE of 14.56%, though net income declined to $1.28B in 2025. Recent contract wins with Aramco in Saudi Arabia and TotalEnergies in Suriname highlight growth opportunities, while analyst consensus is strongly bullish with a $44.78 price target.
Outlook remains positive due to strategic contracts and oil price support from geopolitical tensions, but risks include Middle East volatility and cost pressures. The stock offers value with earnings beats and institutional backing, though investors should monitor debt levels and execution on new projects.
Moderna (MRNA) trades at $60.47, down 2.18% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported a net loss of -$2.82B in 2025, with revenue declining to $1.92B, though it has beaten EPS estimates in recent quarters. Recent news highlights progress in its cancer pipeline, including a Phase 1 study for mRNA-4200, and an EU contract for its RSV vaccine.
The outlook remains speculative with high execution risk as Moderna transitions beyond COVID-19 vaccines. While pipeline advancements offer long-term potential, persistent losses and negative margins pose significant challenges. Analyst consensus is cautious with a $49 price target, suggesting limited near-term upside amid ongoing fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
